Detection of Androgen Receptor Gene Polymorphism in Sudanese Patients of Prostate Cancer in Khartoum State

Jumaa Abuajila Salem Salama a, Dawelbiet Abdelaal Yahia b, Mohamed Maysara Ali b, Ahmed Elhadi Elsadig c* and Tarig A. M. Hamid d

a Department of biochemistry, College of Medicine, University of Zawia, Libya.  
b Department of biochemistry, College of Medicine, University of El Imam El Mahadi, Sudan.  
c Department of Haematology, Faculty of Medical Laboratory Sciences, Alzaiem Al Azhari University, Khartoum, Sudan.  
d Department of Hematology and Immunohematology, Sharq El Nile College, Khartoum North, Sudan.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JCTI/2022/v12i430184

Received 18 May 2022  
Accepted 20 July 2022  
Published 01 August 2022

ABSTRACT

Background: Prostate cancer (PCa) is the most commonly diagnosed solid tumor among men. Genetic susceptibility had been proposed among the risk factors for the development of this cancer.

Aim: To investigate the effect of androgen receptor gene polymorphism in the susceptibility of prostate cancer among Sudanese patients.

Methods: This study was conducted in Khartoum State during the period from December 2021 to May 2022. The study population that was selected consisted of one hundred patients, who had prostate cancer, who attended for routine follow-up assessment following their chemotherapy treatment. A total of 5 ml EDTA anti-coagulated venous blood samples were obtained from all participants. Prostate specific antigen (PSA) was measured by competitive chemiluminescence immunoassay. DNA extraction was performed for all samples by chemical method and genotyping was performed by PCR-RFLP method using Eco147I enzyme.

Results: The Androgen receptor genotype showed that wild (G/G) type was more frequent (89%) than heterozygous (G/A) type (11%), and allele G was more frequent (94.5%) than allele A (5.5%).

*Corresponding author: Email: aabdalla3@gmail.com;
The mean serum PSA level among prostate cancer patients was 18.71 ± 31.68 ng/ml. Comparison of the mean serum PSA levels between different AR genotypes revealed no significant association between the genotype and the hormonal level (p. values > 0.05).

**Conclusion:** Androgen receptor gene polymorphism was detected in this study population as heterozygous type. Moreover; there was no significant association between AR genotype and serum PSA level.

**Keywords:** Androgen receptor (AR); prostate cancer (PCa); PSA-Sudan.

1. **INTRODUCTION**

Prostate cancer is a major public health problem worldwide. Prostate cancer is estimated to be a major cancer of men in several sub-Saharan African countries, and African-Americans have higher rates of prostate cancer incidence and mortality compared to men of other ancestries, particularly in the younger age groups [1-3]. Prostate cancer mortality rate is generally high in black population [1]. Despite this, no published data are currently available for prostate cancer in the Sudan, and prostate cancer is not included in the major cancer series from Central Sudanese hospitals. This is most probably the consequence of multiple combined factors, including little attention to prostate cancer screening, lack of diagnostic facilities, scarce disease awareness, comparatively low life expectancy and young population structure. Yet, prostate cancer is considered the second among cancers in Sudan, with a high mortality rate [1].

The androgen receptor (AR) (NR3C4, nuclear receptor subfamily 3, group C, gene 4) belongs to the steroid hormone group of nuclear receptors with the estrogen receptor (ER), glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) [4,5,6]. The AR is a ligand-dependent transcription factor that controls the expression of specific genes. The binding of the AR to its native ligands 5α-dihydrotestosterone (DHT) and testosterone initiates male sexual development and differentiation.

Mutation of AR, especially mutations that result in a relaxation of AR ligand specificity, may contribute to the progression of prostate cancer and the failure of endocrine therapy by allowing AR transcriptional activation in response to antiandrogens or other endogenous hormones. Similarly, alterations in the relative expression of AR co-regulators have been found to occur with prostate cancer progression and may contribute to differences in AR ligand specificity or transcriptional activity. Prostate cancer progression is also associated with increased growth factor production and an altered response to growth factors by prostate cancer cells. The kinase signal transduction cascades initiated by mitogenic growth factors modulate the transcriptional activity of AR and the interaction between AR and AR coactivators. The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression (Heinlein and Chang, 2004).

The aim of the current study is to illustrate the etiological role of AR polymorphism in prostate cancer among Sudanese subjects.

2. **MATERIALS AND METHODS**

This study was undertaken in Khartoum state during the period from January 2018 to January 2021. A total of One hundred prostate cancer patients were included in this study. Patients who had other form of malignancies were excluded. Venous blood (5 ml) samples were collected in EDTA tubes from all participants. Serum prostate specific antigen (PSA) levels were measured by competitive chemiluminescence immunoassay. The remainder of the blood samples were kept under liquid nitrogen (AT -20°C) until used for genotyping.

DNA was extracted by chemical method. Genotyping was performed by PCR-RFLP method using Eco147I enzyme at 37°C. PCR and digestion products were visualized on 1.5% agarose electrophoresis.

Data were analyzed by statistical package for social science (SPSS), version 16. Qualitative data were presented as mean and SD.

3. **RESULTS**

The Androgen receptor genotype showed that wild (G/G) type was more frequent (89%) than heterozygous (G/A) type (11%), and allele G (94.5%) was more frequent than allele A (5.5%).
Table 1. Distribution of androgen receptor polymorphisms among prostate cancer patients

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Patient N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen receptor G/G</td>
<td>89(89.0)</td>
</tr>
<tr>
<td>G/A</td>
<td>11(11.0)</td>
</tr>
<tr>
<td>allele G</td>
<td>189(94.5)</td>
</tr>
<tr>
<td>allele A</td>
<td>11(5.5)</td>
</tr>
</tbody>
</table>

The serum PSA assay revealed that, the mean value among prostate cancer patients was 18.71±31.68 ng/ml. Comparison of the mean PSA levels between different AR genotypes revealed no significant association between the genotype and the hormonal level (p. values > 0.05) (Table 2).

Table 2. Comparison between hormonal parameters and androgen receptor genotypes among prostate cancer patients

<table>
<thead>
<tr>
<th>AR Genotype</th>
<th>PSA ng/ml (Mean ± SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>G/G</td>
<td>18.22±31.66</td>
<td>0.664</td>
</tr>
<tr>
<td>G/A</td>
<td>22.65±33.14</td>
<td></td>
</tr>
</tbody>
</table>

4. DISCUSSION

Prostate cancer is the most common cancer in Sudanese men. Despite the substantial public health impact of prostate cancer little is known about the etiology of prostate cancer. Risk factors for the development of prostate cancer include: advanced age, familial predisposition and potentially ethnicity. The aim of this study was to explore the etiological role of AR polymorphism in prostate cancer among Sudanese subjects.

In the present study, the AR genotyping showed that wild (G/G) type was more frequent than heterozygous (G/A), and the G allele was more frequent than A allele. These figures differ from what had been observed in the study done by Andrea Gsur, et al. [7], in which the AR (G/A) genotype was more frequent (40.0 %) followed by (A/A) type (30.5 %) and (G/G) type was 29.5%.

In the current study the mean results of serum PSA level was significantly increased in patients compared to the control group (p. values = 0.000). The result of our study corresponded to study that was undertaken by Andrea Gsur, et al. [7], which showed statistically significant elevation of mean serum PSA levels in prostate cancer (30.8 ng/ml) when compared to the control group (4.7 ng/ml) (p. value = 0.001).

Similarly, with regard to another study conducted in Omdurman and Soba teaching hospitals in Khartoum-Sudan by Akram H. Awadalla et al. [8], the results showed significant elevation of mean serum PSA level in the cases (23.04±32.26) ng/ml when compared with the control group (1.23±0.89) ng/ml (p. value = 0.000) and could be used as useful prognostic and screening markers for prostate cancer. The results of our study were also in agreement with a study that was undertaken by Zhiang Zhao [9], which found a significant difference in the mean of serum level of prostate specific antigen at cutoff value of 4ng/ml between the patients group (2.07±1.12) and the control group (0.88±0.46) ng/ml (P = 0.014).

In another study which was undertaken by Haala M. Gabra, et al. [10], serum total PSA (42.6±27.2 ng/ml) in the prostate cancer group was found to be higher than that in the Bengin prostatic hyperplasia group (7.8±5.1 ng/ml) (p. value < 0.05).

Finally; in the current study, no statistically significant association between the serum PSA level and AR genotype was found. This is in line with the study that was undertaken by Andrea Gsur, et al. [7], which showed no significant association between the serum PSA level with the AR genotype as the mean serum PSA level among patients with A/A genotype was (4.6 ng/ml) compared to patients with G/A genotype (4.7 ng/ml) and G/G genotype (4.8 ng/ml) with (p. value =0.98).

5. CONCLUSION

Androgen receptor gene polymorphism was detected in this study population as heterozygous type. Moreover; there was no significant association between AR genotype and serum PSA level.

FUNDING

Authors did not receive neither financial nor non-financial funding for conducting and publishing this work.
ETHICAL APPROVAL AND CONSENT

The study was approved by the research committee at the faculty of Medicine, El imam Elmahdi university. Ethical approval was achieved from the university. Informed consents were taken from each subject before enrollment in the study.

ACKNOWLEDGMENTS

Authors gratefully acknowledge all people work and help us in this study especially at institute of tropical diseases of Khartoum.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

9. Zhigang Zhao, Guohua Zeng, Wen Zhong. Serum Early Prostate Cancer Antigen (EPCA) as a Significant Predictor of Incidental Prostate Cancer in Patients Undergoing Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia; the Prostate. 2010;70:1788-1798.

© 2022 Salama et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/88926